Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NBL-012 Phase 1 study in healthy Chinese subjects
NCT05259189Phase 1Completed
- Sponsor
- NovaRock Biotherapeutics
- Start
- Jul 2021
- Primary completion
- May 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in psoriasis, inflammatory bowel disease (IBD) and hidradenitis suppurativa (HS) comparing NBL-012 with Placebo (2 arms). Primary endpoints: Number of participants with treatment-related adverse events as assessed by CTCAE v5.0, Clinically significant changes from baseline in 12-lead electrocardiogram (ECG) examination and 5 more. Started Jul 2021; status: completed.
02
Drugs
NBL-012
03
Conditions
psoriasisinflammatory bowel disease (IBD)hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT05259189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05259189.